Browse by Poster Presenter

Type here to filter the list

V
Vahrmeijer, A.L.

Department of Surgery, Leiden University Medical Center
(P 109) NOVEL CANDIDATE BIOMARKERS FOR FLUORESCENCE IMAGE-GUIDED SURGERY IN GASTROINTESTINAL STROMAL TUMORS
A.L. Vahrmeijer
Favorite
VALCARCEL, ANTONIO

HCU VIRGEN ARRIXACA
(P 318) NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
ANTONIO VALCARCEL
Favorite
Valdagni, Riccardo

Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Dei Tumori
(P 203) MULTIDISCIPLINARY APPROACH OF ADVANCED-STAGE ALVEOLAR RHABDOMYOSARCOMA OF THE MAXILLARY SINUS IN ADULTS: A CASE REPORT
Riccardo Valdagni
Favorite
Valencia, Chrysler

Sarcoma Oncology Center
(P 122) AN UPDATE ON TNT: A PHASE-2 STUDY OF THE EFFICACY AND SAFETY OF TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN IN ADVANCED SARCOMA
Chrysler Valencia
Favorite
(P 123) COMPLETE RESPONSES WITH SAINT PROTOCOL: A PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB, AND TRABECTEDIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (NCT03138161)
Chrysler Valencia
Favorite
(P 126) GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)
Chrysler Valencia
Favorite
(P 132) PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]
Chrysler Valencia
Favorite
(P 133) PHASE 2 COMBINATION REGIMEN WITH TALIMOGENE LAHERPAREPVEC (TVEC), NIVOLUMAB AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA [NCT# 03886311]
Chrysler Valencia
Favorite
(P 137) SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Chrysler Valencia
Favorite
(P 138) SUSTAINED REMISSION/DISEASE CONTROL USING AUTOLOGOUS ENHANCED NATURAL KILLER CELLS PLUS AN IMMUNE CHECKPOINT INHIBITOR AS TREATMENT FOR RARE CHEMOTHERAPY-RESISTANT ADVANCED SOFT TISSUE SARCOMAS
Chrysler Valencia
Favorite
Valentin, Thibaud

Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Thibaud Valentin
Favorite
Valeri, Sergio

Department of Surgery, Policlinico Universitario Campus Bio-Medico
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Sergio Valeri
Favorite
Valero-Arrese, Lorena

Hospital Universitari Vall d'Hebron
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Lorena Valero-Arrese
Favorite
Valiev, Aslan

Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
(P 158) NEOADJUVANT COMBINATION OF DOXORUBICIN, CISPLATIN AND METHOTREXATE IN PATIENTS AGED 24-40 YEARS WITH OSTEOSARCOMA UNDER THE COVERAGE OF HEMODIALYSIS. AMAP2021-7-2. ONGOING TRIAL
Aslan Valiev
Favorite
Vallacchi, Viviana

Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Viviana Vallacchi
Favorite
Vallee, Marc

Deciphera Pharmaceuticals, LLC
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Marc Vallee
Favorite
(P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
Marc Vallee
Favorite
Valverde Morales, Claudia Maria

Vall D'Hebron University Hospital
(P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Claudia Maria Valverde Morales
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Claudia Maria Valverde Morales
Favorite
Valverde, Claudia

Hospital Universitario Valle de Hebrón
(P 148) ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Claudia Valverde
Favorite
van Bodegom-Vos, Leti

Leiden University Medical Center
(P 076) FOLLOW-UP AFTER CURATIVE SURGICAL TREATMENT OF SOFT-TISSUE SARCOMAS: PATIENTS RECEIVING MORE OR LESS VISITIS THAN PROTOCOL AND ASSOCIATIONS WITH RECURRENCE
Leti van Bodegom-Vos
Favorite
(P 079) HEALTH-RELATED QUALITY OF LIFE OF BONE AND SOFT-TISSUE TUMOR PATIENTS AT TIME OF DIAGNOSIS
Leti van Bodegom-Vos
Favorite
Van Cann, Thomas

Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute
(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
Thomas Van Cann
Favorite
van Coevorden, Frits

The Netherlands Cancer Institute
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Frits van Coevorden
Favorite
Van De Rijn, Matt

Stanford University
(P 130) MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS
Matt Van De Rijn
Favorite
van de Sande, Michiel

Leiden University Medical Center, Leiden, Netherlands
(P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
Michiel van de Sande
Favorite
(P 051) NON-INVASIVE DETECTION OF SOFT TISSUE SARCOMA USING VOLATILE ORGANIC COMPOUNDS IN EXHALED BREATH: A PILOT STUDY
Michiel van de Sande
Favorite
(P 076) FOLLOW-UP AFTER CURATIVE SURGICAL TREATMENT OF SOFT-TISSUE SARCOMAS: PATIENTS RECEIVING MORE OR LESS VISITIS THAN PROTOCOL AND ASSOCIATIONS WITH RECURRENCE
Michiel van de Sande
Favorite
(P 079) HEALTH-RELATED QUALITY OF LIFE OF BONE AND SOFT-TISSUE TUMOR PATIENTS AT TIME OF DIAGNOSIS
Michiel van de Sande
Favorite
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Michiel van de Sande
Favorite
van de Wal, Deborah

Netherlands Cancer Institute
(P 115) PSYCHOLOGICAL AND SOCIAL CHALLENGES OF PATIENTS WITH ADVANCED AND METASTATIC GASTROINTESTINAL STROMAL TUMORS ON LONG-TERM TREATMENT WITH TYROSINE KINASE INHIBITORS: A QUALITATIVE STUDY
Deborah van de Wal
Favorite
van Den Akker, Brendy

LUMC
(P 255) TRUNCATED FOS REDUCES OSTEOGENIC DIFFERENTIATION CAPACITY IN OSTEOID OSTEOMA AND OSTEOBLASTOMA
Brendy van Den Akker
Favorite
van der Graaf, Winette

Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Winette van der Graaf
Favorite
(P 115) PSYCHOLOGICAL AND SOCIAL CHALLENGES OF PATIENTS WITH ADVANCED AND METASTATIC GASTROINTESTINAL STROMAL TUMORS ON LONG-TERM TREATMENT WITH TYROSINE KINASE INHIBITORS: A QUALITATIVE STUDY
Winette van der Graaf
Favorite
(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Winette van der Graaf
Favorite
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Winette van der Graaf
Favorite
(P 272) PREGNANCY-ASSOCIATED DESMOID FIBROMATOSIS: A DUTCH MULTI-CENTRE RETROSPECTIVE ANALYSIS
Winette van der Graaf
Favorite
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Winette van der Graaf
Favorite
(P 319) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS; PROTOCOL FOR A SYSTEMATIC REVIEW
Winette van der Graaf
Favorite
van der Hage, Jos

Department of Surgery, Leiden University Medical Center
(P 109) NOVEL CANDIDATE BIOMARKERS FOR FLUORESCENCE IMAGE-GUIDED SURGERY IN GASTROINTESTINAL STROMAL TUMORS
Jos van der Hage
Favorite
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Jos van der Hage
Favorite
Van der Wal, Robert

Leiden University Medical center
(P 051) NON-INVASIVE DETECTION OF SOFT TISSUE SARCOMA USING VOLATILE ORGANIC COMPOUNDS IN EXHALED BREATH: A PILOT STUDY
Robert Van der Wal
Favorite
van Etten, B.
(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
B. van Etten
Favorite
van Ginhoven, Tessa

Erasmus Medical Center
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Tessa van Ginhoven
Favorite
Van Houdt, Winan

The Netherlands Cancer Institute
(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Winan Van Houdt
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Winan Van Houdt
Favorite
(P 272) PREGNANCY-ASSOCIATED DESMOID FIBROMATOSIS: A DUTCH MULTI-CENTRE RETROSPECTIVE ANALYSIS
Winan Van Houdt
Favorite
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Winan Van Houdt
Favorite
Van IJzendoorn, David

Stanford University
(P 255) TRUNCATED FOS REDUCES OSTEOGENIC DIFFERENTIATION CAPACITY IN OSTEOID OSTEOMA AND OSTEOBLASTOMA
David Van IJzendoorn
Favorite
Van Leenders, Geert

Erasmus Medical Center Rotterdam
(P 044) AUTOMATIC SEGMENTATION USING DEEP LEARNING TO DISTINGUISH BETWEEN 9 TYPES OF SOFT-TISSUE TUMORS WITH RADIOMICS
Geert Van Leenders
Favorite
Van Loo, Peter

The University of Texas MD Anderson Cancer Center
(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Peter Van Loo
Favorite
Van Praag, Veroniek

Leiden University Medical center
(P 051) NON-INVASIVE DETECTION OF SOFT TISSUE SARCOMA USING VOLATILE ORGANIC COMPOUNDS IN EXHALED BREATH: A PILOT STUDY
Veroniek Van Praag
Favorite
Van Raemdonck, Dirk

UZ Leuven
(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Dirk Van Raemdonck
Favorite
Van Renterghem, Britt

KU Leuven
(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Britt Van Renterghem
Favorite
Van Tine, Brian

Washington University School of Medicine
(P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Brian Van Tine
Favorite
(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Brian Van Tine
Favorite
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Brian Van Tine
Favorite
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Brian Van Tine
Favorite
Vanacker, Helene

CENTRE LEON BERARD
(P 238) EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Helene Vanacker
Favorite
Vanleeuw, Ulla

Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute
(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
Ulla Vanleeuw
Favorite
(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Ulla Vanleeuw
Favorite
Vanni, Silvia

Osteoncology Unit, Bioscience Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Silvia Vanni
Favorite
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Silvia Vanni
Favorite
Varga, Steven

University of Iowa Carver College of Medicine
(P 159) NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Steven Varga
Favorite
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Steven Varga
Favorite
Vasquez, Juan

Department of Pediatrics, Yale School of Medicine, New Haven, CT
(P 178) HIGH FREQUENCY OF NAPRT-SILENCING IN NEUROBLASTOMA AND RHABDOMYSARCOMA CONFERS SENSITIVITY TO TARGETING OF NAD+ METABOLISM USING NAMPT INHIBITORS
Juan Vasquez
Favorite
Vaz-Salgado, María Ángeles

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
María Ángeles Vaz-Salgado
Favorite
Venkatramani, Rajkumar

Baylor College of Medicine
(P 155) LATE EVENTS OCCURRING AFTER 5 YEARS IN PEDIATRIC RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Rajkumar Venkatramani
Favorite
Vera, Jacqueline

Memorial Sloan Kettering Cancer Center
(P 04) EXPERT PANEL REVIEW OF THE PRO-AYA: PARTIENT-REPORTED OUTCOMES FOR ADOLESCENTS AND YOUNG ADULTS WITH CANCER
Jacqueline Vera
Favorite
Verbeeck, Kimberly

KU Leuven
(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Kimberly Verbeeck
Favorite
Vercauteren, Suzanne

BC Children's Hospital, University of British Columbia
(P 033) REDUCED H3K27ME3 IMMUNOEXPRESSION IN PEDIATRIC OSTEOSARCOMA IS ASSOCIATED WITH POOR RESPONSE TO NEOADJUVENT THERAPY
Suzanne Vercauteren
Favorite
Verhoef, Cornelis

Erasmus Medical Center
(P 044) AUTOMATIC SEGMENTATION USING DEEP LEARNING TO DISTINGUISH BETWEEN 9 TYPES OF SOFT-TISSUE TUMORS WITH RADIOMICS
Cornelis Verhoef
Favorite
(P 051) NON-INVASIVE DETECTION OF SOFT TISSUE SARCOMA USING VOLATILE ORGANIC COMPOUNDS IN EXHALED BREATH: A PILOT STUDY
Cornelis Verhoef
Favorite
(P 272) PREGNANCY-ASSOCIATED DESMOID FIBROMATOSIS: A DUTCH MULTI-CENTRE RETROSPECTIVE ANALYSIS
Cornelis Verhoef
Favorite
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Cornelis Verhoef
Favorite
Verite, Cécile

CHU Bordeaux
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Cécile Verite
Favorite
Vern-Gross, Tamara

Department of Radiation Oncology, Mayo Clinic
(P 202) LONG-TERM EXPERIENCE WITH INTRAOPERATIVE ELECTRON RADIATION THERAPY BOOST IN EXTREMITY SARCOMA
Tamara Vern-Gross
Favorite
Verret, Benjamin

Institute Gustave Roussy- paris
(P 217) PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
Benjamin Verret
Favorite
Vijayakumar, Gayathri

Rush University Medical Center
(P 053) PET-CT STAGING AFFECTS TIME TO TREATMENT IN SARCOMA
Gayathri Vijayakumar
Favorite
(P 062) WHAT IS THE CLINICAL IMPACT OF STAGING AND SURVEILLANCE PET-CT SCAN FINDINGS IN PATIENTS WITH BONE AND SOFT TISSUE SARCOMA?
Gayathri Vijayakumar
Favorite
(P 081) MISSING DATA IN THE DEVELOPMENT AND EXTERNAL VALIDATION OF MACHINE LEARNING MODELS FOR SURVIVAL PREDICTION IN SARCOMA
Gayathri Vijayakumar
Favorite
(P 086) RADIOTHERAPY, VOLUME REDUCTION, AND SHORT-TERM SURGICAL OUTCOMES IN THE TREATMENT OF LARGE MYXOID LIPOSARCOMAS
Gayathri Vijayakumar
Favorite
(P 094) TOTAL KNEE ARTHROPLASTY FOR OSTEOARTHRITIS IS UNCOMMON AFTER INTRALESIONAL CURETTAGE IN GIANT CELL TUMOR OF BONE
Gayathri Vijayakumar
Favorite
(P 206) RADIOTHERAPY LEADS TO IMPROVED OVERALL SURVIVAL IN PATIENTS UNDERGOING RESECTION FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Gayathri Vijayakumar
Favorite
(P 227) ASSOCIATION BETWEEN NEUTROPHIL-LYMPHOCYTE RATIO, PLATELET-LYMPHOCYTE RATIO, AND SURVIVAL IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Gayathri Vijayakumar
Favorite
(P 283) HIP ARTHROPLASTY OUTCOMES IN METASTATIC BONE DISEASE
Gayathri Vijayakumar
Favorite
(P 294) PERCUTANEOUS STABILIZATION OF PATHOLOGIC FRACTURES OF THE PELVIS AND SACRUM
Gayathri Vijayakumar
Favorite
Villamayor-Delgado, María

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
María Villamayor-Delgado
Favorite
Villanueva, Andre

Yong Loo Lin School of Medicine, National University of Singapore
(P 196) THERAPEUTIC VULNERABILITY AND RESISTANCE DURING PROGRESSION OF AN AGGRESSIVE SOLITARY FIBROUS TUMOUR
Andre Villanueva
Favorite
Villarejo, Pedro juan

Fundación Jiménez diaz
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Pedro juan Villarejo
Favorite
Vincenzi, Bruno

Università Campus Bio-Medico di Roma
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Bruno Vincenzi
Favorite
(P 162) PAZOPANIB IN THE REAL-WORLD SETTING: DATA FROM THE ITALIAN NATIONAL REGISTRY
Bruno Vincenzi
Favorite
Vincenzi, Bruno

Campus Bio-Medico University of Rome
(P 185) PHARMACOLOGICAL INHIBITION OF GLYOXALASE-1 AS NOVEL THERAPEUTIC STRATEGY TO POTENTIATE TRABECTEDIN ANTI-TUMOR EFFECT IN SOFT TISSUE SARCOMA PRECLINICAL MODELS
Bruno Vincenzi
Favorite
Visgauss, Julia

Duke
(P 034) REGIONAL ANESTHESIA IMPROVES METASTASIS FREE SURVIVAL AFTER SURGICAL RESECTION OF BONE SARCOMAS
Julia Visgauss
Favorite
(P 288) LOCKING PLATE AUGMENTATION OF POLYMETHYLMETHACRYLATE-FILLED DISTAL FEMUR DEFECTS
Julia Visgauss
Favorite
Visser, Jacob

Erasmus Medical Center Rotterdam
(P 044) AUTOMATIC SEGMENTATION USING DEEP LEARNING TO DISTINGUISH BETWEEN 9 TYPES OF SOFT-TISSUE TUMORS WITH RADIOMICS
Jacob Visser
Favorite
Vizzaccaro, Salvatore

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Salvatore Vizzaccaro
Favorite
Vogely, Clementine

Department of Surgery, Leiden University Medical Center
(P 109) NOVEL CANDIDATE BIOMARKERS FOR FLUORESCENCE IMAGE-GUIDED SURGERY IN GASTROINTESTINAL STROMAL TUMORS
Clementine Vogely
Favorite
Voliotis, Dimitris

Zentalis
(P 144) A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY OF ZN-C3 PLUS GEMCITABINE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Dimitris Voliotis
Favorite
von Mehren, Margaret

Fox Chase Cancer Center
(P 096) AN OPEN-LABEL, PHASE 2 EFFICACY STUDY OF TEMOZOLOMIDE IN ADVANCED SUCCINATE DEHYDROGENASE-MUTANT/DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Margaret von Mehren
Favorite
(P 221) SURGICAL OUTCOMES OF NEOADJUVANT THERAPY FOR GASTROINTESTINAL STROMAL TUMORS: A SINGLE INSTITUTION ANALYSIS
Margaret von Mehren
Favorite
(P 234) DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Margaret von Mehren
Favorite
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Margaret von Mehren
Favorite
Vora, Tushar

Princess Margaret Cancer Center
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Tushar Vora
Favorite
Vornicova, Olga

Sinai Healthcare System
(P 191) SYNERGISTIC ACTIVITY OF PARP INHIBITORS IN COMBINATION WITH STANDARD CHEMOTHERAPY IN LEIOMYOSARCOMA
Olga Vornicova
Favorite